AR049512A1 - Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas - Google Patents

Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas

Info

Publication number
AR049512A1
AR049512A1 ARP050102402A ARP050102402A AR049512A1 AR 049512 A1 AR049512 A1 AR 049512A1 AR P050102402 A ARP050102402 A AR P050102402A AR P050102402 A ARP050102402 A AR P050102402A AR 049512 A1 AR049512 A1 AR 049512A1
Authority
AR
Argentina
Prior art keywords
alkyl
aryl
halomethyl
hydroxy
group
Prior art date
Application number
ARP050102402A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34957878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049512(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR049512A1 publication Critical patent/AR049512A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

Los compuestos pertenecen a la categoría de derivados de tetrahidrofurano condensados utilizados para prevencion y tratamiento de trastornos psiquiátricos y neurologicos por su afinidad de union hacia receptores de serotonina, dopamima y con propiedades de inhibicion de la recaptacion de norepinefrina. Composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de formula (1), su sal de adicion de ácido o de base farmacéuticamente aceptable, su forma estereoquímicamente isomérica, su forma de N-oxido y su profármaco, donde: n es un numero entero igual a 0,1, 2, 3, 4, 5 o 6; p es un numero entero igual a 0, 1, 2, 3 o 4; q es un numero entero igual a 0, 1, 2, 3 o 4; r es un numero entero igual a 0, 1, 2, 3, 4 o 5; R1 y R2 cada uno se selecciona, independientemente, del grupo de hidrogeno; alquilo C1-6; alquil C1-6-carbonilo; halometilcarbonilo; arilo; alquilsulfonilo y alquilo C1-6 sustituido con hidroxi, alquiloxi C1-6, carboxilo, alquil C1-6 carboniloxi, alquiloxi C1-6 carbonilo o arilo; o R1 y R2 en forma conjunta con el átomo de nitrogeno al cual están unidos pueden formar un anillo morfolinilo o un radical del grupo de formulas (2), donde: R9, R10, R11 y R12 cada uno independientemente se selecciona del grupo de hidrogeno; halo; halometilo y alquilo C1-6; m es un numero entero igual a 0, 1, 2, o 3; R13, R14, R15 y R16 cada uno se selecciona independientemente del grupo de hidrogeno; alquilo C1-6; arilo y arilcarbonilo; o R15 y R16 en forma conjunta pueden formar un radical bivalente alcanodiilo C4-5; R17 se selecciona del grupo de hidrogeno; alquilo C1-6; alquil C1-6 carbonilo; halometilcarbonilo; alquiloxi C1-6 carbonilo; arilo; di(aril) metilo; alquilo C1-6 sustituido con hidroxi, alquiloxi C1-6, carboxilo, alquil C1-6 carboniloxi, alquiloxi C1-6 carbonilo y arilo; cada R3 se selecciona, independientemente, del grupo de hidrogeno; halo; ciano; hidroxi; halometilo; halometoxi; carboxilo; nitro; amino; mono- o di(alquil C1-6) amino; alquil C1-6 carbonilamino; aminosulfonilo; mono- o di(alquil C1-6) aminosulfonilo; alquilo C1-6; alquiloxi C1-6; alquil C1-6 carbonilo y alquiloxi C1-6 carbonilo; cada R4 se selecciona, independientemente, del grupo de hidrogeno; halo; ciano; hidroxi; halometilo; halometoxi; carboxilo; nitro; amino; mono- o di(alquil C1-6) amino; alquil C1-6 carbonilamino; aminosulfonilo; mono- o di(alquil C1-6) aminosulfonilo; alquilo C1-6; alquiloxi C1-6; alquil C1-6 carbonilo y alquiloxi C1-6 carbonilo; cada R5 se selecciona, independientemente, del grupo de alquilo C1-6; ciano y halometilo; R6 y R7 cada uno, independientemente del otro, se selecciona del grupo de hidrogeno, hidroxi, alquilo C1-6, halometilo y alquiloxi C1-6; con la condicion de que R6 y R7 no sean simultáneamente hidrogeno; o R6 y R7 tomados en forma conjunta puedan formar un radical metileno (=CH2); o, junto con el átomo de carbono al cual están unidos, un carbonilo; y arilo es fenilo; o fenilo sustituido con 1, 2 o 3 sustituyentes seleccionados del grupo de halo, hidroxi, alquilo C1-6 y halometilo.
ARP050102402A 2004-06-14 2005-06-13 Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas AR049512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2004051105 2004-06-14

Publications (1)

Publication Number Publication Date
AR049512A1 true AR049512A1 (es) 2006-08-09

Family

ID=34957878

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102402A AR049512A1 (es) 2004-06-14 2005-06-13 Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas

Country Status (15)

Country Link
US (1) US20070197525A1 (es)
EP (1) EP1761514B1 (es)
JP (1) JP2008502649A (es)
CN (1) CN1968942B (es)
AR (1) AR049512A1 (es)
AT (1) ATE402932T1 (es)
AU (1) AU2005251948A1 (es)
CA (1) CA2567847A1 (es)
DE (1) DE602005008596D1 (es)
DK (1) DK1761514T3 (es)
ES (1) ES2311228T3 (es)
PL (1) PL1761514T3 (es)
PT (1) PT1761514E (es)
TW (1) TW200612899A (es)
WO (1) WO2005121113A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ562008A (en) * 2005-05-26 2010-03-26 Janssen Pharmaceutica Nv Novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives and their use as a medicament
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
AU2009335709A1 (en) 2008-12-19 2011-07-14 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
CA2793222C (en) 2010-03-31 2018-01-23 Supernus Pharmaceuticals, Inc. Stabilized formulations of cns compounds
WO2013018899A1 (ja) * 2011-08-03 2013-02-07 協和発酵キリン株式会社 ジベンゾオキセピン誘導体
WO2013189920A1 (en) 2012-06-19 2013-12-27 Ucb Pharma S.A. New compound based on cinchona alkaloïds for use in asymmetric michael addition
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3350405A (en) * 1964-10-16 1967-10-31 Sterling Drug Inc Amino-lower-alkoxy-dibenzo [a, d] cyclohepten-5-ones and 10, 11-dihydro derivatives thereof
US3507920A (en) * 1964-10-16 1970-04-21 Sterling Drug Inc Hydroxydibenzo(a,d)cyclohepten-5-ones and esters and ethers thereof
US3565956A (en) * 1964-10-16 1971-02-23 Sterling Drug Inc Amino-lower-alkoxy-5-alkylidene-dibenzo(a,d)cycloheptenes
US3562331A (en) * 1964-10-16 1971-02-09 Sterling Drug Inc Amino-lower-alkoxy-dibenzo(a,d)cycloheptene-5-carbinols
US3812119A (en) * 1969-11-21 1974-05-21 Ciba Geigy Corp Dibenzocycloheptenes
PT892793E (pt) * 1996-04-12 2003-08-29 Janssen Pharmaceutica Nv Derivados 2-cianoiminoimidazolo inibidores da pde iv
UA52778C2 (uk) * 1997-10-10 2003-01-15 Янссен Фармацевтика Н.В. Галогенозаміщені тетрациклічні похідні тетрагідрофурану, спосіб їх отримання та композиція на їх основі
US6998494B2 (en) * 2001-12-07 2006-02-14 Janssen Pharmaceutica N.V. Preparation of trans-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives

Also Published As

Publication number Publication date
DK1761514T3 (da) 2008-12-01
ATE402932T1 (de) 2008-08-15
WO2005121113A1 (en) 2005-12-22
EP1761514A1 (en) 2007-03-14
US20070197525A1 (en) 2007-08-23
CN1968942A (zh) 2007-05-23
JP2008502649A (ja) 2008-01-31
PL1761514T3 (pl) 2009-01-30
ES2311228T3 (es) 2009-02-01
PT1761514E (pt) 2008-10-28
CA2567847A1 (en) 2005-12-22
AU2005251948A1 (en) 2005-12-22
DE602005008596D1 (de) 2008-09-11
CN1968942B (zh) 2011-06-15
TW200612899A (en) 2006-05-01
EP1761514B1 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
AR049512A1 (es) Derivados de tetrahidrofurano tetraciclicos. composiciones farmaceuticas
AR045386A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR071314A1 (es) Antagonistas de receptor de cgrp
AR066881A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR066882A1 (es) Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato.
AR044475A1 (es) Derivados de 2-amino -piridina utiles para el tratamiento de enfermedades
AR035759A1 (es) Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
HRP20100283T8 (en) Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
AR078638A1 (es) Antagonistas del receptor de cgrp
RS50561B (sr) Derivati sulfonamida za lečenje bolesti
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
WO2008101935A3 (fr) Nouveaux composés dérivés d'indole et compositions pharmaceutiques les contenant
ATE484502T1 (de) Neue verbindungen
MY169179A (en) Novel piperidine compound or salt thereof
RU2014121205A (ru) Производные азолов
CR20190261A (es) Inhibidores de la tirosina quinasa de bruton
AR115920A1 (es) Inhibidores tipo indol y azaindol de enzimas pad
AR053835A1 (es) Tetrahidropiridoazepin - 8 - onas como moduladores del receptor de dopamina d2 y compuestos relacionados para el tratamiento de la esquizofrenia y otros trastornos del snc, composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos.
PE20200756A1 (es) Compuestos de indazol como potenciadores alostericos mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica
RS52851B (en) CYCLOPROPYL AMID DERIVATIVES AIMING THE HISTAMINE H3 RECEPTOR
EA200970793A1 (ru) Модуляторы рецепторов, активируемых пролифераторами пероксисом

Legal Events

Date Code Title Description
FA Abandonment or withdrawal